Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2017
Price : $35 *
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms CoBRIM-B
- 04 Apr 2016 According to ClinicalTrials.gov status changed from recruiting to discontinued due to slow accrual.
- 23 Jun 2015 Status changed from not yet recruiting to recruiting, according to an abstract presented at 51st Annual Meeting of the American Society of Clinical Oncology
- 29 May 2015 Trial design presented at 51st Annual Meeting of the American Society of Clinical Oncology.